Erector spinae plane block for abdominal pain from gastrointestinal cancer
Official title: Efficacy of the Erector Spinae Plane Block for Abdominal Pain From Gastrointestinal Malignancies
Run by Abramson Cancer Center at Penn Medicine · NCT07211386 · Data updated 2026-11-12
This study will try an erector spinae plane nerve block to reduce severe abdominal pain and opioid use in adults with gastrointestinal cancers who come to Penn Medicine emergency departments.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 25 (estimated) |
| Sponsor | Abramson Cancer Center at Penn Medicine Academic / other |
| Locations | 4 sites (Philadelphia, Pennsylvania and 3 other locations) |
| Status | Recruiting |
| Started | December 11, 2025 |
| Main results expected | May 15, 2027 |
| Study ends | June 15, 2027 |
| Registry record updated | November 28, 2025 |
| Trial ID | NCT07211386 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (over 18) with known gastrointestinal malignancy who present to a participating Penn Medicine ED with intractable abdominal pain and a same-day or recent CT showing a malignant source, who are medically stable and able to consent, are the intended participants.
✕Probably not a fit
Patients with non-malignant causes of pain, hemodynamic instability, allergy to ropivacaine or history of local anesthetic toxicity, pregnancy, incarceration, inability to consent, admission for serial abdominal exams, or prior enrollment are unlikely to be eligible or to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project will offer an erector spinae plane block (ESPB), a regional anesthetic technique, to adults with GI malignancy who present to Penn Medicine EDs with intractable abdominal pain. Eligible patients receiving ESPB will be enrolled as a prospective cohort and compared to a matched historical control group of similar patients treated with standard ED analgesia. The primary outcome is total opioid use over 24 hours measured in milligram morphine equivalents (MMEs), with secondary outcomes including hospital length of stay and pre/post-block pain, function, and satisfaction at 24 hours. The ESPB will be performed by ED providers per institutional protocols already in use at UPHS.
Why it matters
Potential benefit: If successful, the ESPB could lower opioid needs and pain levels and possibly shorten hospital stays for patients with cancer-related abdominal pain.
How similar studies have gone: Regional anesthesia techniques including ESPB have shown pain and opioid-sparing benefits in perioperative and acute pain case series and small trials, but high-quality evidence specifically for ED management of GI cancer pain is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients age \> 18 years old with GI malignancy presenting to a Penn Medicine ED with intractable abdominal pain. 2. Same-day or recent CT scan of the abdomen / pelvis which demonstrates that the patient's abdominal pain can be reasonably attributed to a malignant source. Exclusion Criteria: 1. Allergy to ropivacaine or history of local anesthetic systemic toxicity. 2. Pregnancy 3. Incarcerated 4. Patients being admitted for serial abdominal examinations to determine their surgical course. 5. Altered mental status or inability for patient to consent for the procedure 6. Hemodynamic instability 7. Previously enrolled in the study
Where it's running
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States Recruiting -
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania, United States Recruiting -
Pennsylvania Hospital
Philadelphia, Pennsylvania, United States Recruiting -
Hospital of the University of Pennsylvania -- Cedar Avenue
Philadelphia, Pennsylvania, United States Recruiting
Study contacts
- Principal investigator: Michael Shalaby, MD — University of Pennsylvania Department of Emergency Medicine
- Study coordinator: Umar Aulia, AB
- Email: umar.aulia@pennmedicine.upenn.edu
- Phone: 267-624-4394
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pain control options for children having distal radius fracture reductions
This will test whether a hematoma block with low-dose ketamine or a hematoma block with intranasal fentanyl controls pain as well as full IV ketamine sedation for children aged 3–17 who need a distal radius fracture reduced.
-
Virtual rooms testing how control and environment change pain, anxiety, and memory.
This study tries to see if having control over pain in different virtual rooms changes how much pain and anxiety people feel and how well they do on memory and navigation tasks in healthy adults without major psychiatric or chronic pain conditions.
-
Monitoring heart health in patients receiving 5-FU chemotherapy
This study is testing if using a heart monitor at home can help keep track of heart health in patients getting 5-FU chemotherapy for cancer.
-
M-TAPA vs ESPB for lung function after gallbladder removal
This trial tests whether two ultrasound-guided nerve blocks, M-TAPA and ESPB, better preserve postoperative lung function and reduce pain after laparoscopic cholecystectomy.
-
Comparing two ultrasound-guided chest nerve blocks for pain control after VATS
This test compares an erector spinae plane block and a serratus anterior plane block to see which gives better pain relief for adults having video-assisted thoracoscopic surgery (VATS).
-
Multimodal regional nerve blocks to improve recovery after off-pump CABG
This study tests whether using multiple regional nerve blocks can reduce pain and help patients recover after off-pump coronary artery bypass surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.